5. Approximately 13% of the dose was eliminated in urine and feces in 28 days, with fecal elimination accounting for about 10% of the dose.
which increases chloride transport (Cloutier et al., 1990 , Cloutier et al., 1993 , Molina y Vedia et al., 1996 , Henke et al., 1998 and water mobilization (Molina y Vedia et al., 1996 , Henke et al., 1998 when applied to the apical surface of the airway epithelium.
Because of these properties it may be a useful treatment for cystic fibrosis (CF), a genetic disease characterized by abnormal chloride ion transport. This abnormal chloride transport alters the water content of the airway mucus, impairing its clearance and leading to infection, inflammation, lung disease and death. Moli1901 can increase the chloride permeability in nasal epithelium from healthy volunteers and CF patients (Zeitlin et al., 2004) and it can increase the volume of airway surface liquid in normal dogs (Molina y Vedia et al., 1996 , Henke et al. 1998 . The therapeutic goal for the treatment of CF and other pulmonary diseases like asthma and chronic bronchitis in which the water content of the mucus is altered, is to remove retained secretions from the lungs.
The known pharmacokinetic profile of Moli1901 is intriguing. The molecule is poorly absorbed after inhalation exposure, intratracheal instillation or oral administration in rats and after oral administration in mice (McNulty et al., 2003) . The main route of elimination in rats was the feces. The half-life of disappearance from the respiratory tract after intratracheal instillation was 64 days and there was no degradation or metabolism of the compound present in this tissue. The half-life of elimination in the feces in these animals was 52 days (McNulty et al., 2003) . Plasma and blood concentrations of Moli1901-related radioactivity were always less than 1ng eq.ml -1 and could not be accurately measured. A preliminary study (McNulty et al., 1997) in dogs in which the animals inhaled aerosolized 3 H-labeled Moli1901 provided data suggesting that absorption from the lung was slow in this species as well. As in the rat model, accurate measurements of circulating Moli1901-related material were not possible in the dog, and the major route of elimination was the feces.
In preparation for determination of Moli1901 disposition in humans, it was important to determine the systemic exposure to Moli1901-related material in dogs after exposure via the respiratory tract. Carbon-14-labeled Moli1901 was used as a tracer to avoid the possibility of erroneous disposition data due to 3 H exchange. At the same time, a methodology that would quantify low amounts of 14 C-labeled compound, allowing its application in future human studies was needed. Accelerator Mass Spectrometry (AMS) is an extremely sensitive and precise technique for quantifying certain rare, long-lived isotopes such as carbon-14 and was chosen to quantify the 14 C-Moli1901 in this study. AMS quantifies isotopic nuclei, rather than radioactive decay, resulting in 10 3 -10 9 fold increase in sensitivity compared to the decay counting methods that are widely employed in radioisotope tracer studies (reviewed by Turteltaub and Vogel, 2000) .
In this paper we describe the kinetics, distribution and elimination of 14 CMoli1901 in beagle dogs after instillation of the dose into the left cranial lobe of the lung.
14 C-Moli1901-related radiocarbon is slowly absorbed, achieves only very low concentrations in the circulation and major organs, and is slowly eliminated in the feces.
Materials and Methods
Chemicals. Unlabeled and All other tissues were homogenized in an approximately equal volume of water.
Aliquots were taken and frozen until analysis by AMS.
Sample analysis. AMS was used to measure the ratio of 14 C to total carbon in aliquots of whole blood, plasma, urine, feces, bile, liver, kidney, spleen, lung and brain. Samples were thawed at room temperature, and an aliquot of each sample (20 µl blood, 50 µl plasma, 100 µl urine, 10-20 mg feces, 25-50 µl of bile and homogenate from liver brain, lung, kidney and spleen) were placed in quartz tubes and dried in a vacuum centrifuge. The samples were converted to CO 2 by combustion, and the CO 2 was quantitatively reduced to graphite in the presence of zinc and titanium hydride, condensing onto cobalt at approximately 500 ºC for 4 hours (Vogel, 1992 , Ognibene et al., 2003 . The carbon ratios of the graphite samples were then quantified using the 1MV accelerator mass spectrometer at Lawrence Livermore National Laboratory (Ognibene et al., 2002) . Between three and seven replicate measurements were recorded for each sample. All measurements were normalized to similarly prepared standards of known carbon isotope ratios.
The carbon ratios of "Time 0 hours" or "Day 0" whole blood, plasma, urine and fecal samples for each dog were subtracted from the isotope ratios of the other The carbon content (w/w percentage carbon) was measured using an Exeter 440 CHN Analyzer, using at least 3 replicates for each sample type. The average values found and used in calculations were: plasma--3.3%, whole blood--11.0%, feces--12.8%, bile--11.8%, kidney--6.1%, spleen--8.3%, brain--6.4%, liver--7.9%, left caudal lung lobe--5.0% and right cranial lung lobe--4.6%.
As the percentage carbon is more variable in urine (in this study it ranged from 0.2-3.1%), each individual urine sample was analyzed for carbon content.
The limit of quantitation of the AMS analysis is calculated as the mean plus 3 times the SD of the background (i.e., the control samples). Controls from whole blood, plasma, urine and feces were used for this calculation. (table 2) , and the total ng equivalents/g lung remained fairly constant between 72 and 672 hours. The percent dose remaining in the lobe did decrease, however. This is because the animals got slightly different total doses due to body weight differences.
Results

Blood and Plasma Concentrations of
[Insert excretion was also constant, but at a higher rate in two of the three dogs ( figure   1 ).
[Insert figure 1 about here.]
Excretion in feces was more rapid during the first four days after the dose than it was thereafter (figure 2). From approximately Day 5 through Day 28 fecal elimination was slow, but constant.
[Insert figure 2 about here.]
Discussion
The data in this paper are consistent with those reported previously for rats, mice and dogs (McNulty et al., 1997 (McNulty et al., , 2003 in that Moli1901-related material disappears slowly from lungs after an inhalation or instillation dose, and it is slowly excreted, primarily in the feces. Based on earlier data (McNulty et al., 1997 (McNulty et al., , 2003 it is probable that little or no metabolism of Moli1901 occurred. It is quite likely that most of the Moli1901-related material appearing in the feces is the result of swallowing the compound subsequent to mucociliary clearance from the lungs.
Of the tissues examined, excluding the site of administration, kidney and lung contained the highest concentrations of Moli1901-related material. In rats given an intravenous dose of the compound (McNulty et al., 2003) , the highest concentrations were found in spleen and liver. No explanation for this difference in distribution of absorbed Moli1901-related material is readily apparent from the data gathered.
The concentration of Moli1901-related material in blood and plasma declined at first and then rose toward the end of the experimental period. This suggests that the compound was being removed more slowly from blood than it was being added by absorption from the lung or from the gastrointestinal tract after swallowing (see above). Furthermore, as the time after the dose increased, so did the proportion of Moli1901-related material associated with the cellular fraction of blood. Several studies have shown that Moli1901 interacts with membrane phospholipids (Navarro et al., 1985 , Sokolove et al., 1989 . The NMR analysis from Wakamatsu et al. (1990) indicates that a biological analog to Moli1901 named Ro90198 differing only in one residue (Lys present in
Moli1901 is replaced by Arg in Ro90198) binds to the polar head of phosphatidyl ethanolamine (PE). We have confirmed that Moli1901 possesses this same property (Molina, unpublished data). In addition, Choung et al. (1988) and Aoki et al. (1994) A similar association with membrane lipids may account for the slow removal of Moli1901-related material from the site of application in the lung. Alternatively, the slow removal of the compound from the lung may be due to the size and molecular weight of Moli1901 limiting its absorption. While peptides with more amino acid residues such as insulin (51 residues) and growth hormone (192 residues) can be absorbed from the lungs of humans and animals in active form (reviewed in Patton and Platz, 1992) , the structure of Moli1901 differs from those molecules in having several intramolecular bonds. These intramolecular bonds may force the compound into retaining a 3-dimensional structure with a greater molecular radius than insulin or growth hormone.
Studies of model peptide transport across rat alveolar cell monolayers have demonstrated that absorption is primarily paracellular and is inversely related to molecular radius (Dodoo et al., 2000) .
The data in this study are consistent with data in the previous study of inhaled aerosolized 3 H-Moli1901 in dogs. In both studies, a significant portion (50-65%) of the dose of radiolabel remained in lung tissue at 4 weeks after dose administration, although in the earlier study, the radiolabel was more evenly distributed in lung tissue. This is an expected result given that the dose was delivered to all lobes of the lung in that study. In both studies fecal elimination was the primary route of excretion, and the bulk of the fecal excretion occurred over the first couple of days.
Moli1901 is currently in the clinic and has proven to be safe in single dose studies in human volunteers and CF patients by the inhalation route. Although technically challenging, determination of the half-life or residence time in the lung, as well as the biodistribution and excretion are long term goals of the project. This study in dogs demonstrates the feasibility of the execution of a full clinical protocol using 14 C-Moli1901 and AMS to attain those objectives. 
